Objective: To determine the role of protein-with-molecular-weight-53 (p53), burkit cell lymphoma 2 (Bcl2), Fas ligand (FasL) mRNA, and vascular cell adhesion molecule 1 (VCAM-1), known as the apoptosis-related molecular pathway, in preeclamptic patients.
Introduction
Preeclampsia in pregnancy is characterized by blood pressure of ≥140/90 mmHg in two or more measurements which is accompanied by proteinuria (30 mg/dL) in two separate tests with a nominal measurement scale. There are three stages involved in the pathogenesis of preeclampsia: abnormal vascular remodeling of placenta, placental ischemia, and endothelial cell dysfunction. 1 Some previous studies have hypothesized that the causes of preeclampsia originally involve genetic, immunological, and other factors resulting in a failure in trophoblast proliferation and invasion. These factors lead to abnormal placental vascular remodeling and endothelial dysfunction, causing the syndrome of preeclampsia.
Protein-with molecular weight-53, or p53, protects cells against the deoxyribonucleic acid (DNA) damage.
2 DNA damage and hypoxia, which increases the phosphorylation of p53, occur when metabolic processes enhance the role of p53 and decrease murine double minute-2 protein (MDM-2) that will ultimately enhance the role of p53 in apoptosis. [2] [3] [4] However, the biosynthetic mechanisms associated with p53 and apoptosis in pregnancy are not known. 2, 5 In the intrinsic pathway of apoptosis, the mitochondrial genes are primarily regulated by burkit cell lymphoma 2 (Bcl2). Tissue samples from patients with preeclampsia have shown that the expression of the antiapoptotic protein Bcl2 is lower than that of patients with normal pregnancy. Increased apoptotic activity in the placental bed of preeclampsia patients inhibits trophoblast invasion into the spiral artery. 6 The ligand receptor pathway, or the extrinsic pathway, is mediated by cytokines such as the tumor necrotic factor alpha (TNFα) and Fas ligand (FasL). FasL/Fas plays an important role in protecting the fetus from the maternal immune system. In mouse experiments, FasL played a role to prevent changes in immune cell activation between the maternal-fetal surface. This showed a decreased expression of FasL on the surface of decidual leukocyte infiltration and enhanced placental fetal death. 6, 7 The number of markers indicating endothelial dysfunction increase in the blood or urine of preeclamptic women. Most of these markers, including the vascular cell adhesion molecule 1 (VCAM-1) and cellular fibronectin, increase during several weeks of pregnancy. Placental ischemia occurs due to hypoxia, which is presumed to be related to the vascular endothelial damage. This condition is characterized by increased levels of VCAM-1. Increased levels of VCAM-1 improve the regulation of the apoptotic caspase cascade. The apoptosis that occurs in preeclampsia may occur through the intrinsic and extrinsic pathways. The role of p53, Bcl2, and FasL messenger ribonucleic acid (mRNA) in apoptosis in preeclampsia and the uncertainty in which apoptotic pathway The specimens were taken from the placental tissue, immediately after the placenta was born. Using tweezers and a scalpel, the placental tissue was cut approximately 2x2 cm in size and put in a sterile tube and received label for the RNA expression inspection: p53, Bcl2 and FasL in real time-polymerase chain reaction (PCR). The placental specimens were immediately frozen in liquid nitrogen, then stored in the freezer with a temperature of -80 °C until it was used.
Clinical examination
The physical examination performed in this study included the general condition, weight, height, as well as a heart and lung examination. Systolic and diastolic blood pressure were also measured after the patient rested for 15 minutes on her left side. The blood pressure was the average of two examinations performed at 5-minute intervals.
Determination of VCAM-1 levels
The levels of VCAM-1 protein were determined in duplicate experiments by using the enzymelinked immunosorbent assay (ELISA) with the human VCAM-1 immunoassay kit (Quantikine) in Glyceraldehydes-3-phosphate dehydrogenase (GAPDH) was used for normalization. The p53 fragment was isolated using 5'AGA GTC TAT AGG CCC ACC CC3' forward primer and 5'GCT CGA CGC TAG GAT CTG AC3' reverse primer following the reseach of Ohtani. 8 The Bcl2 fragment was isolated using 5'GAC AGA AGA TCA TGC CGT CC3' forward primer and 5'GGT ACC AAT GGC ACT TCA AG3', the Bcl2 fragment was 76 bp, reverse primer based on the research by Mbazima. 9 The FasL fragment was isolated using 5'GCA GCC CTT CAA TTA CCC AT3' forward primer and 5'CAG AGG TTG GAC AGG GAA GAA3', the FasL fragment was 101 bp, reverse primer based on the research by Das. test, Pearson's correlation and the regression test (which is used to compare two groups of subjects or bivariate) as well as the multiple logistic regression test (multivariate). The data analysis was performed using SPSS ver. 13.0 at a 95% confidence interval (p≤0.05).
Results
Identification of preeclamptic subjects (n=31) were made based on preeclampsia clinical diagnosis which includes the presence of hypertension (>140/90 mmHg). Normortensive pregnant women were included as the control subjects (n=31). The main clinical parameters include gestational age, body mass index, age, and parity (Table 1) . During the period of July 2009 and April 2010, a continuous series of 31 preeclamptic patients were studied. No significant differences were found between the preeclamptic and normal pregnancies in terms of gestational age, BMI, maternal age, and parity (Table 1) . Therefore, the characteristics of both groups can be considered homogeneous and the results of subsequent examinations can be considered as comparable.
Based on the Chi-square test, a significant correlation was seen between the incidence of preeclampsia and VCAM-1(p=0.001), p53 mRNA expression (p=0.010) and Bcl2 mRNA (p=0.041), whereas the FasL mRNA expression showed no significant relationship with the incidence of preeclampsia (p=0.300) ( Table 2) . Multivariable tests were performed on variables that had a value of p<0.25 (Table 3) .
Multiple logistic regression analysis showed that the most dominant molecule associated with the incidence of preeclampsia was VCAM-1 (OR=16.77), which indicates that the levels of VCAM-1 are not normal, showing a 17-fold higher incidence risk for preeclampsia than the normal levels of VCAM-1. This result shows that VCAM-1 is the most dominant risk factor in predicting the incidence of preeclampsia (p<0.001). For the preeclamptic group, there was a significantly negative correlation between the levels of p53 and VCAM-1 (p=0.005 and r=0.490) which indicates a weak association. For the normal pregnancy group, there was a significantly negative correlation between p53 and higher levels of VCAM-1 (p=0.0200 and r=0.415), indicating a weak association. There was a negative but statistically insignificant correlation between the levels of Bcl2 and VCAM-1 (p=0.093 and r=0.619) in the preeclamptic group, indicating that the power of the correlation is weak. For the normal pregnancy group, there was a negative correlation between the levels of Bcl2 and VCAM-1, but this correlation was not statistically significant (p=0.278 and r=0.201), indicating that the correlation is very weak ( Table 4 ). The correlation between the levels of Bcl2/p53 ratio and VCAM-1 in the preeclamptic group was significantly positive (p=0.002 and r=0.541) which indicates a weak relationship. In the normal pregnancy group, there was no significant positive correlation (p=0.595 and r=0.099), indicating that the strength of the correlation is very weak ( Table 5 ).
Discussion
The symptoms of hypertension associated with preeclampsia is developed during pregnancy and disappear after birth. This condition suggested that the placenta plays an important role as a source of preeclampsia. There is growing evidence for the notion that the dysfunction of endothelial cells is the major contributor to preeclampsia. Although the mechanism of the activation of endothelial dysfunction is already well understood, there is evidence suggesting that leukocytes play a role in this destructive process. Endothelial dysfunction leads to increased levels of VCAM-1 in the blood or urine of women with preeclampsia several weeks before and during pregnancy. The mean levels of VCAM-1 in the preeclampsia group were higher (1,077.63 ng/ mL) than the controls (823.99 ng/mL), (p=0.006). VCAM-1 indicates the presence of inflammation in preeclampsia. The inflammation results from endothelial damage; therefore, VCAM-1 is a marker of endothelial damage. 11 In our study, medium levels of VCAM-1 (>890.08 ng/mL) were not significantly associated with preeclampsia (p=0.401). This result is understandable because there are many factors that trigger preeclampsia other than the endothelial damage. One of the factors that allegedly contribute to triggering the onset of preeclampsia is apoptosis as a result of placental hypoxia leading to placental ischemia.
Our study indicated that the levels of VCAM-1 were high (>890.08 ng/mL) in 23 preeclampsia individuals (74.2%), compared to only 10 in the control group (32.3%), whereas 8 individuals (25.8%) of the preeclampsia case group and 21 individuals of the control group (67.7%) showed low levels of VCAM-1 (<890.08 ng/mL). This result is consistent with the theory that placental ischemia plays a role in preeclampsia syndrome; whereas in preeclampsia, increased adhesion molecule expression in the maternal circulation and elevated levels of homocysteine are found. Elevated level of VCAM-1 is one of the Mintareja Teguh, Made Kornia Karkata, et al.
:23-9 characteristics of the endothelial dysfunction, resulting in a lack of uteroplacental perfusion. Uteroplacental insufficiency leads to the release of free radicals and induces hypoxia. Hypoxia is thought to cause the increased phosphorylation of p53 if there is an increased metabolic process at the level of the p53 gene and reduces the role of MDM-2, which will ultimately enhance the role of p53 in the apoptotic process. The relationship between p53 mRNA expression and the incidence of preeclampsia was significant (p=0.010, Table 2 ). These results are consistent with in vitro and in vivo models. 6, 12 The p53 gene protects cells against DNA damage and plays a role in DNA repair. The loss or inactivation of p53 would result in the disruption of genetic equilibrium.
The relation between the level of Bcl2 mRNA expression and the incidence of preeclampsia (Table 2) in this study was significant (p=0.041). This result is consistent with the theory that the pathway that is more involved in the hypoxic conditions in preeclampsia is the more dominant intrinsic pathway in which the expression of Bcl2 decreased to induce apoptosis. It has been hypothesized that hypoxia would cause the loss of Bcl2 and/or Bcl-XL from the mitochondrial membrane and these proteins would be replaced by proapoptotic proteins, such as Bak, Bax and Bim. Our results on Bcl2 are in agreement with the results from previous reports. 13, 14 The FasL/Fas pathway is one of the body's main pathways to control placental apoptosis. Extrinsic pathways are thought to be the pathogenesis of preeclampsia. As reported by Laskowska 15 , when apoptosis occurred in normal pregnancy, a more advanced stage of pregnancy was associated with a higher rate of apoptosis in placentas. In preeclamptic pregnancies, CD4+ T cells produce more Th1 cytokines, such as IL2, IFNα and TNFβ, which induce an increase in apoptosis. This result was shown by Zou et al. 16 who showed that a large concentration of IFNα induced the increased expression of FasL/ Fas. 16 The results of the multivariable analysis of the relationship between risk factors (Table  3 ). The mRNA expression levels of p53 and Bcl2 and VCAM-1 levels were associated with preeclampsia, and VCAM-1 was the primary risk factor in predicting the incidence of preeclampsia (p< 0.001).
The results of this study showed a significant negative correlation between the expression of p53 mRNA and VCAM-1 levels in both the preeclampsia and normal pregnancy groups. The possible absence of correlation between VCAM-1 and p53 may be due to many other factors that cause endothelial dysfunction in addition to VCAM-1, such as LDL, ICAM1, PECAM1 and von Willebrand factor VIII. It was reported on a study that a significant increase in ICAM1 expression but not VCAM-1 expression was found in preeclampsia. This result is in contrast with reports by Ohtani et al. 8 who showed that ICAM1, VCAM-1, E-selectin and PECAM1 levels were significantly elevated in preeclampsia. It is possible that these results could explain the negative correlation between the expression of p53 and Bcl2 mRNA with VCAM-1 levels.
In summary, these results indicate a positive weak correlation between the Bcl2/p53 ratio and higher levels of VCAM-1 in the preeclamptic group. In the normal pregnancy group, there is a very weak positive correlation between the Bcl2/ p53 ratio and higher levels of VCAM-1. These results show that increases in the Bcl2/p53 ratio will be followed by elevated levels of VCAM-1 in preeclampsia, in which the expression of p53 would affect the balance of Bcl2 and Bax, as an intrinsic pathway of apoptosis in the mitochondrial membrane and the occurrence of placental apoptosis resulting in hypoxia. Hypoxia will increase the levels of free radicals that cause damage to endothelial cells which is characterized by increased levels of VCAM-1.
